Protein anchors as a newly discovered key molecule in cancer spread and epilepsy

The signaling protein MTOR (Mechanistic Target of Rapamycin) is a sensor for nutrients such as amino acids and sugars. When sufficient nutrients are available, MTOR boosts metabolism and ensures that sufficient energy and cellular building blocks are available. Since MTOR is a central switch for metabolism, errors in its activation lead to serious diseases. Cancers and developmental disorders of the nervous system leading to behavioral disorders and epilepsy can be the result if MTOR is malfunctioning.

Therefore, the cell controls MTOR activity very precisely with the help of so-called suppressors. These are molecules that inhibit a protein and help to regulate its activity. The-TSC complex is such a suppressor for MTOR. It is named after the disease that causes its absence -- tuberous sclerosis (TSC). The TSC complex is located together with MTOR at small structures in the cell, the so-called lysosomes, where it keeps MTOR in check. If the TSC complex -- for example due to changes in one of its components -- no longer remains at the lysosome, this can lead to excessive MTOR activity with severe health consequences.

Protein with an anchor function

The teams led by Christiane Opitz at DKFZ and Kathrin Thedieck at the University of Innsbruck therefore investigated how the TSC complex binds to lysosomes. They discovered that the G3BP proteins (Ras GTPase-activating protein-binding protein) are located together with the TSC complex on lysosomes. "There, the G3BP proteins form an anchor that ensures that the TSC complex can bind to the lysosomes," explains Mirja Tamara Prentzell of DKFZ, first author of the publication. This anchor function plays a crucial role in breast cancer cells. If the amount of G3BP proteins is reduced in cell cultures, this not only leads to increased MTOR activity, but also increases cell migration.

Drugs that inhibit MTOR prevent this spread, the researchers were able to show in cell cultures. In breast cancer patients, low levels of G3BP correlate with a poorer prognosis. "Markers like the G3BP proteins could be helpful to personalize therapies based on inhibition of MTOR," explains Kathrin Thedieck, professor of biochemistry at the University of Innsbruck. The good thing is that drugs that inhibit MTOR are already approved as cancer drugs and could be tested specifically in further studies.

G3BP proteins also inhibit MTOR in the brain. In zebrafish, an important animal model, the researchers observed disturbances in brain development when G3BP is absent. This leads to neuronal hyperactivity similar to epilepsy in humans. These neuronal discharges could be suppressed by drugs that inhibit MTOR. "We therefore hope that patients with rare hereditary neurological diseases in which dysfunctions of the G3BP proteins play a role could benefit from drugs against MTOR," says Christiane Opitz of DKFZ. In the future, the scientists plan to investigate this together with their Europe-wide research network.